Mammoth Biosciences snags $45 mln Series B

South San Francisco-based Mammoth Biosciences, a provider of a CRISPR-based disease detection platform, has raised $45 million in Series B funding.

South San Francisco-based Mammoth Biosciences, a provider of a CRISPR-based disease detection platform, has raised $45 million in Series B funding. Decheng Capital led the round with participation from other investors that included Mayfield, NFX, Verily, Brook Byers, Plum Alley, Pacific 8 and aMoon.

Source: Press Release